Replies to post #187278 on Avid Bioservices Inc (CDMO)

[stockweiser]

Does NIVO do what BAVI does?

[nuke661]

Wook,

I saw this video yesterday while surfing and before my wife put me to work. I saw the Nivolumab label and discounted it being Bavi. I just assumed there are more cell surface targets other than just PS that can have a basic MOA description similar to Bavi. If it is PS they are targeting then they certainly weren't broadcasting it. Notice they weren't specific in the video regarding the target.

I thought it might be PS targeting experiments by a BP to check PS out themselves using patent loopholes for research. This is just a wild ass possibility line of thinking I had because the MOA for Nivolumab doesn't sound anything like what was described in the video and there is nothing directly connecting the label on the IV bag directly to the drug being discussed. They never said what the drug was and only provided the MOA cartoon.


Nivolumag MOA Info
Source

MECHANISM OF ACTION OF NIVOLUMAB In vitro, nivolumab binds to PD-1 on activated human T cells with high affinity (half maximal effective concentration [EC50]: 0.64 nM by FACS analysis and 2.6 nM by Scatchard), and inhibits the binding of PD-1 to its ligands, programmed death-ligand-1 (PD-L1) and programmed death-ligand-2 (PD-L2) (half maximal inhibitory concentration [IC50] of ~1 nM).1 Nivolumab binds specifically to PD-1 and not to related members of the CD28 family such as CD28, inducible co-stimulator (ICOS), cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and B and T lymphocyte attenuator (BTLA). Blockade of the PD-1 pathway by nivolumab results in a reproducible enhancement of both proliferation and IFN- release in the models

[dia76ca]

I agree that the video is talking about a Nivolumab trial. But that makes the latest Bavi pre-clinical results all the more interesting!

PR/8-11-14: New PreClin. data on Bavi’s Immune-Stimulatory MOA presented at 9th ImVacS in Boston

8-11-14: Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
• Combination Mediated Impressive Increase in Tumor-Fighting T-Cells and Significantly Reduce Tumor Growth by Over 78% as Compared to Anti-PD-1 Alone
• Combination Data Show Synergies That Enhance the Effectiveness of Recently Approved and Experimental Immuno-Oncology Treatments That Extend the Duration and Effectiveness of Tumor Fighting T-Cells
• Results Build on Data Seen in Studies Combining Bavituximab With Anti-CTLA-4 or Anti-PD-1 Antibody in Models of Melanoma and Colon Cancer
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=865454